BioCryst Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $218,250 | $156,413 | $406,555 | $159,395 |
Gross Profit | 214,410 | -546,725 | 396,639 | 156,873 |
EBITDA | 98,691 | -699,968 | 266,196 | 32,126 |
EBIT | 98,178 | -701,029 | 262,152 | 31,791 |
Net Income | 78,395 | -721,812 | 245,845 | 12,899 |
Net Change In Cash | 218,250 | 156,413 | 406,555 | 159,395 |
Free Cash Flow | 104,133 | -62,539 | 275,234 | 40,280 |
Cash | 154,972 | 172,445 | 89,736 | 84,078 |
Basic Shares | 265,165 | 242,258 | 219,263 | 219,885 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $874,837 | $450,712 | $331,412 | $270,827 |
Gross Profit | 855,762 | 438,227 | 326,751 | 264,233 |
EBITDA | 347,652 | 12,808 | -116,335 | -143,854 |
EBIT | 346,263 | 11,562 | -117,990 | -145,291 |
Net Income | 263,861 | -88,881 | -226,539 | -247,116 |
Net Change In Cash | 874,837 | 450,712 | 331,412 | 270,827 |
Free Cash Flow | 327,412 | -53,144 | -97,309 | -163,201 |
Cash | 89,736 | 104,923 | 110,643 | 304,767 |
Basic Shares | 218,581 | 206,696 | 192,198 | 185,908 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | $0.30 |
2026-03-31 | $0.14 |
2025-12-31 | $1.12 |
2025-09-30 | $0.16 |